Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer.

Khawaja MR, Jameson G, Cridebring D, Shannon P, Han H, Moore J, Von Hoff D, Posner RG, Hlavacek WS, Kolch W, Kholodenko BN, Rukhlenko OS, Roe DJ, Wertheim BC, Borazanci E

Open source

DOI: 10.36401/jipo-25-20
Published: 2026 Feb
Container: Journal of immunotherapy and precision oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.36401/jipo-25-20,
  title = {Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer.},
  author = {Khawaja MR and Jameson G and Cridebring D and Shannon P and Han H and Moore J and Von Hoff D and Posner RG and Hlavacek WS and Kolch W and Kholodenko BN and Rukhlenko OS and Roe DJ and Wertheim BC and Borazanci E},
  year = {2026},
  journal = {Journal of immunotherapy and precision oncology},
  doi = {10.36401/jipo-25-20},
  url = {https://doi.org/10.36401/jipo-25-20}
}

RIS

TY  - JOUR
TI  - Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer.
AU  - Khawaja MR
AU  - Jameson G
AU  - Cridebring D
AU  - Shannon P
AU  - Han H
AU  - Moore J
AU  - Von Hoff D
AU  - Posner RG
AU  - Hlavacek WS
AU  - Kolch W
AU  - Kholodenko BN
AU  - Rukhlenko OS
AU  - Roe DJ
AU  - Wertheim BC
AU  - Borazanci E
PY  - 2026
JO  - Journal of immunotherapy and precision oncology
DO  - 10.36401/jipo-25-20
UR  - https://doi.org/10.36401/jipo-25-20
ER  -

APA

MR, K., G, J., D, C., P, S., H, H., J, M., D, V. H., RG, P., WS, H., W, K., BN, K., OS, R., DJ, R., BC, W., & E, B. (2026). Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer.. Journal of immunotherapy and precision oncology. https://doi.org/10.36401/jipo-25-20

Source records

pubmed · retrieved 2026-09-26T08:14:11.167Z